Related Experiment Video
Updated: Sep 28, 2025

05:35
Ovarian Cancer Patient-Derived Organoid Models for Pre-Clinical Drug Testing
Published on: September 15, 2023
1.7K
Abstract:
The MEK1/2 inhibitor trametinib increases progression-free survival from 7.2 months to 13 months in women with recurrent low-grade serous ovarian cancer. The drug also boosts the overall response rate from 6% to 26%.

